Please login to the form below

Not currently logged in
Email:
Password:

World markets data from IMS

According to IMS 2006 data, audited figures for the UK pharmaceutical market showed recovery. Having experienced a decline of 2.2 per cent in 2005, the UK expanded its market in 2006 by 4.1 per cent to USD 21bn.

According to IMS 2006 data, audited figures for the UK pharmaceutical market showed recovery. Having experienced a decline of 2.2 per cent in 2005, the UK expanded its market in 2006 by 4.1 per cent to USD 21bn.

The five major EU markets of France, Germany, Italy, Spain and the UK taken together, however, experienced slowing growth for the third year running at only 4.4 per cent, down from 4.8 per cent in 2005.

North America also strengthened its pharmaceutical market in comparison to last year, when growth was just 5.4 per cent. The impact of the first year of the Medicare Part D benefit and the resulting increase in prescribing volume led to a market increase of 8.3 per cent in 2006.

The Chinese pharma market grew a massive 12.4%, although this had slowed from 20.5 per cent in 2005, due to the government's introduction of a campaign to limit physician promotion of pharmaceuticals.

India was one of the fastest growing markets in 2006, with pharmaceutical sales increasing 17.5 per cent to USD 7.3bn, helped by lower GDP per capita income in that region.

6th August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments....
Keith Berelowitz
Transforming clinical trials to accelerate drug development
...
How the WHO hepatitis strategy measures up in the field
With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...